in vivo cDNA Synthesis Technologies.

Invivoscribe holds world-wide exclusive rights to the following patent, which covers in vivo complementary DNA synthesis technologies:
United States Patent Number 6,498,025

PCR-based testing of the Immunoglobulin and T cell Receptor Loci.

Invivoscribe Technologies holds world-wide exclusive rights to the following patents for the identification and monitoring of leukemias, lymphomas, and other lymphoproliferative diseases using any amplification based technology, including PCR:
United States Patents Numbered 5,296,351 and 5,418,134
Australian Patent Number 626,601
Japanese Patent Number 2,781,438

Nucleic acid amplification primers for PCR-based clonality studies.

Invivoscribe holds the world-wide exclusive license to intellectual property covering methods and compositions developed by the EuroClonality/BIOMED-2 Clonality Group, with the right to use and apply methods and the right to manufacture, market, offer for sale and sell products in affiliation with the BIOMED-2 Clonality Group.  Further, the license limits affiliation of BIOMED-2 Clonality Group to Invivoscribe only and allows Invivoscribe to use the name of the BIOMED-2 Clonality Group in marketing and sales materials.
Notice of Allowance: European Patent Number 03756746.8
United States Patent Pending 60/417,779
International Patent Pending PCT/NL2003/000690
International Patent Pending WO/2004/033728

Nucleic acid encoding receptor type protein kinase, FLT3.

Invivoscribe Technologies holds a worldwide exclusive license (ex-Japan) to develop, manufacture, use, and sell testing reagents for FLT3/ITD mutation detection. We are both prosecuting existing patents and preparing a number of additional patent applications covering this technology to ensure that we maximize the breadth of claims and solidify our already comprehensive IP coverage. Issued patents and patent applications currently pending that are licensed exclusively to IVS include:
United States Patent Number 6,846,630
European Patent Pending 0959132B1
United States Patent Pending 20100093988
International Patent Pending PCT/JP97/03667

Nucleophosmin protein (NPM1) mutants, corresponding gene sequences and uses thereof.

Invivoscribe holds rights to use technologies related to the following patents and patent applications:
International Patent Pending PCT/IT2005/000634
International Patent Pending WO 2006/046270
Canadian Patent Application 2585965